Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 1/2014

01.01.2014 | Original Article

Predictors of malignancy in primary aldosteronism

verfasst von: Ayman Agha, Matthias Hornung, Igors Iesalnieks, Andreas Schreyer, Ernst Michael Jung, Assad Haneya, Hans J. Schlitt

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Primary aldosteronism (PA, also Conn syndrome) is a benign disease in majority of cases. However, malignant transformation has been described. Present study reports on three cases of aldosterone producing adrenocortical carcinoma (APAC) in comparison to patients with benign PA.

Patients and methods

Data of patients undergoing adrenalectomy for benign PA were compared to patients with APAC. Retrospective chart analysis was performed. All patients received spironolactone for 6–8 weeks preoperatively.

Results

Seventy-four patients underwent adrenalectomy for PA between 1994 and 2011. Three of them revealed an APAC. Patients with APAC presented with a significantly lower serum potassium level (1.7 mmol/l vs. 3.4 mmol/l, p = 0.001) and significant larger tumors (5.2 vs. 1.8 cm, p = 0.002). In addition, aldosterone/renin (A/R) ratio 675 in patients with APAC as compared to 74 in patients with benign PA (p = 0.0001). Sixty-eight of 71 patients with benign PA underwent minimal invasive surgery, whereas all three patients with APAC were operated conventionally. All patients with APAC developed disease recurrence 6–18 months postoperatively.

Conclusion

Tumor size >4 cm and a very high A/R ratio seems to predictors of malignancy in patients with PA. If these criteria are present, open adrenalectomy should be performed instead of endoscopic procedure.
Literatur
1.
Zurück zum Zitat Fardella CE, Mosso L, Gomez-Sanchez C et al (2000) Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85(5):1863–1867PubMedCrossRef Fardella CE, Mosso L, Gomez-Sanchez C et al (2000) Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85(5):1863–1867PubMedCrossRef
2.
Zurück zum Zitat Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85(8):2854–2859PubMedCrossRef Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85(8):2854–2859PubMedCrossRef
3.
Zurück zum Zitat Mosso L, Carvajal C, Gonzalez A et al (2003) Primary aldosteronism and hypertensive disease. Hypertension 42(2):161–165PubMedCrossRef Mosso L, Carvajal C, Gonzalez A et al (2003) Primary aldosteronism and hypertensive disease. Hypertension 42(2):161–165PubMedCrossRef
4.
Zurück zum Zitat Young WF Jr (2003) Mini review: primary aldosteronism—changing concepts in diagnosis and treatment. Endocrinology 144(6):2208–2213PubMedCrossRef Young WF Jr (2003) Mini review: primary aldosteronism—changing concepts in diagnosis and treatment. Endocrinology 144(6):2208–2213PubMedCrossRef
5.
Zurück zum Zitat Mulatero P, Stowasser M, Loh KC et al (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89(3):1045–1050PubMedCrossRef Mulatero P, Stowasser M, Loh KC et al (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89(3):1045–1050PubMedCrossRef
6.
Zurück zum Zitat McKenzie TJ, Lillegard JB, Young WF Jr, Thompson GB (2009) Aldosteronomas—state of the art. Surg Clin N Am 89(5):1241–1253PubMedCrossRef McKenzie TJ, Lillegard JB, Young WF Jr, Thompson GB (2009) Aldosteronomas—state of the art. Surg Clin N Am 89(5):1241–1253PubMedCrossRef
7.
Zurück zum Zitat Zinnamosca L, Petramala L, Cotesta D et al (2010) Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report. Endocrine 38(3):313–319PubMedCrossRef Zinnamosca L, Petramala L, Cotesta D et al (2010) Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report. Endocrine 38(3):313–319PubMedCrossRef
8.
Zurück zum Zitat Conn JW (1955) Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45(1):3–17PubMed Conn JW (1955) Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45(1):3–17PubMed
9.
Zurück zum Zitat Born-Frontsberg E, Reincke M, Rump LC et al (2009) Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 94(4):1125–1130PubMedCrossRef Born-Frontsberg E, Reincke M, Rump LC et al (2009) Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 94(4):1125–1130PubMedCrossRef
10.
Zurück zum Zitat Foye LV Jr, Feichtmeir TV (1955) Adrenal cortical carcinoma producing solely mineralocorticoid effect. Am J Med 19(6):966–975PubMedCrossRef Foye LV Jr, Feichtmeir TV (1955) Adrenal cortical carcinoma producing solely mineralocorticoid effect. Am J Med 19(6):966–975PubMedCrossRef
11.
Zurück zum Zitat Ng L, Libertino JM (2003) Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169(1):5–11PubMedCrossRef Ng L, Libertino JM (2003) Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169(1):5–11PubMedCrossRef
12.
Zurück zum Zitat Mattsson C, Young WF Jr (2006) Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2(4):198–208PubMedCrossRef Mattsson C, Young WF Jr (2006) Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2(4):198–208PubMedCrossRef
13.
Zurück zum Zitat Salassa TM, Weeks RE, Northcutt RC, Carney JA (1975) Primary aldosteronism and malignant adrenocortical neoplasia. Trans Am Clin Climatol Assoc 86:163–172PubMedCentralPubMed Salassa TM, Weeks RE, Northcutt RC, Carney JA (1975) Primary aldosteronism and malignant adrenocortical neoplasia. Trans Am Clin Climatol Assoc 86:163–172PubMedCentralPubMed
14.
Zurück zum Zitat Taylor HC, Douglas JG, Berg GJ, Bravo EL (1982) Primary aldosteronism caused by adrenal cortical carcinoma. Endocrinol Jpn 29(6):701–708PubMedCrossRef Taylor HC, Douglas JG, Berg GJ, Bravo EL (1982) Primary aldosteronism caused by adrenal cortical carcinoma. Endocrinol Jpn 29(6):701–708PubMedCrossRef
15.
Zurück zum Zitat Farge D, Pagny JY, Chatellier G, Plouin PF, Corvol P (1988) [Malignant adrenal cortex carcinoma revealed by an isolated picture of primary hyperaldosteronism]. Arch Mal Coeur Vaiss 81 Spec No:83-87. Farge D, Pagny JY, Chatellier G, Plouin PF, Corvol P (1988) [Malignant adrenal cortex carcinoma revealed by an isolated picture of primary hyperaldosteronism]. Arch Mal Coeur Vaiss 81 Spec No:83-87.
16.
Zurück zum Zitat Ludvik B, Niederle B, Roka R, Schernthaner G, Neuhold N (1988) Malignant aldosteronoma in the differential diagnosis of Conn syndrome. Acta Med Austriaca 15(4):117–120PubMed Ludvik B, Niederle B, Roka R, Schernthaner G, Neuhold N (1988) Malignant aldosteronoma in the differential diagnosis of Conn syndrome. Acta Med Austriaca 15(4):117–120PubMed
17.
Zurück zum Zitat Nakov N, Vladov V, Kolarski V, Dodev K, Rashkov R (1991) 2 cases of primary hyperaldosteronism. Vutr Boles 30(2):115–121PubMed Nakov N, Vladov V, Kolarski V, Dodev K, Rashkov R (1991) 2 cases of primary hyperaldosteronism. Vutr Boles 30(2):115–121PubMed
18.
Zurück zum Zitat Deckers S, Derdelinckx L, Col V, Hamels J, Maiter D (1999) Peritoneal carcinomatosis following laparoscopic resection of an adrenocortical tumor causing primary hyperaldosteronism. Horm Res 52(2):97–100PubMedCrossRef Deckers S, Derdelinckx L, Col V, Hamels J, Maiter D (1999) Peritoneal carcinomatosis following laparoscopic resection of an adrenocortical tumor causing primary hyperaldosteronism. Horm Res 52(2):97–100PubMedCrossRef
19.
Zurück zum Zitat Sakai N, Yamada T, Asao T, Murayama T (1997) Aldosterone-producing adrenocortical carcinoma metastases found seven years after adrenalectomy. Int J Urol 4(1):79–82PubMedCrossRef Sakai N, Yamada T, Asao T, Murayama T (1997) Aldosterone-producing adrenocortical carcinoma metastases found seven years after adrenalectomy. Int J Urol 4(1):79–82PubMedCrossRef
20.
Zurück zum Zitat Yang C, Qiang W, Li L, Lin Y, Zhu J, Han S (2001) Clinical analysis of 149 cases of aldosterone-producing adrenal cortical neoplasms. Zhonghua Wai Ke Za Zhi 39(12):937–939PubMed Yang C, Qiang W, Li L, Lin Y, Zhu J, Han S (2001) Clinical analysis of 149 cases of aldosterone-producing adrenal cortical neoplasms. Zhonghua Wai Ke Za Zhi 39(12):937–939PubMed
21.
Zurück zum Zitat Sweeney AT, Blake MA, Aish LS et al (2002) A malignant aldosteronoma. Endocr Pract 8(5):373–377PubMedCrossRef Sweeney AT, Blake MA, Aish LS et al (2002) A malignant aldosteronoma. Endocr Pract 8(5):373–377PubMedCrossRef
22.
Zurück zum Zitat Honda M, Tsukada T, Horiuchi T et al (2004) Primary hyperparathyroidism associated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern Med 43(4):310–314PubMedCrossRef Honda M, Tsukada T, Horiuchi T et al (2004) Primary hyperparathyroidism associated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern Med 43(4):310–314PubMedCrossRef
23.
Zurück zum Zitat Sun X, Ayala A, Castro CY (2005) Adrenocortical carcinoma with concomitant myelolipoma in a patient with hyperaldosteronism. Arch Pathol Lab Med 129(6):e144–e147PubMed Sun X, Ayala A, Castro CY (2005) Adrenocortical carcinoma with concomitant myelolipoma in a patient with hyperaldosteronism. Arch Pathol Lab Med 129(6):e144–e147PubMed
24.
Zurück zum Zitat Abma EM, Kluin PM, Dullaart RP (2008) Malignant aldosterone-producing adrenal tumour: reoccurrence with glucocorticoid excess without hyperaldosteronism. Neth J Med 66(6):252–255PubMed Abma EM, Kluin PM, Dullaart RP (2008) Malignant aldosterone-producing adrenal tumour: reoccurrence with glucocorticoid excess without hyperaldosteronism. Neth J Med 66(6):252–255PubMed
25.
Zurück zum Zitat Parajo A, Firvida JL, Otero E, Garcia M, Montero M (2000) Isolated primary hyperaldosteronism caused by adrenocortical carcinoma. Arch Esp Urol 53(10):931–934PubMed Parajo A, Firvida JL, Otero E, Garcia M, Montero M (2000) Isolated primary hyperaldosteronism caused by adrenocortical carcinoma. Arch Esp Urol 53(10):931–934PubMed
26.
Zurück zum Zitat Yoshimoto T, Naruse M, Ito Y et al (2000) Adrenocortical carcinoma manifesting pure primary aldosteronism: a case report and analysis of steroidogenic enzymes. J Endocrinol Investig 23(2):112–117 Yoshimoto T, Naruse M, Ito Y et al (2000) Adrenocortical carcinoma manifesting pure primary aldosteronism: a case report and analysis of steroidogenic enzymes. J Endocrinol Investig 23(2):112–117
27.
Zurück zum Zitat Dixon AN, Bing RF (2001) Two cases of adrenocortical carcinoma presenting as Conn's syndrome. J Hum Hypertens 15(1):75–79PubMedCrossRef Dixon AN, Bing RF (2001) Two cases of adrenocortical carcinoma presenting as Conn's syndrome. J Hum Hypertens 15(1):75–79PubMedCrossRef
29.
Zurück zum Zitat Hiramatsu K, Yamada T, Yukimura Y et al (1981) A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 141(12):1589–1593PubMedCrossRef Hiramatsu K, Yamada T, Yukimura Y et al (1981) A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 141(12):1589–1593PubMedCrossRef
30.
Zurück zum Zitat Mulatero P, Rabbia F, Milan A et al (2002) Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40(6):897–902PubMedCrossRef Mulatero P, Rabbia F, Milan A et al (2002) Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40(6):897–902PubMedCrossRef
31.
Zurück zum Zitat Diederich S, Bidlingmaier M, Quinkler M, Reincke M (2007) Diagnosis of primary hyperaldosteronism. Med Klin (Munich) 102(1):16–21CrossRef Diederich S, Bidlingmaier M, Quinkler M, Reincke M (2007) Diagnosis of primary hyperaldosteronism. Med Klin (Munich) 102(1):16–21CrossRef
32.
Zurück zum Zitat Rios MC, Izquierdo A, Sotelo M et al (2011) Aldosterone/renin ratio in the diagnosis of primary aldosteronism. Medicina (B Aires) 71(6):525–530 Rios MC, Izquierdo A, Sotelo M et al (2011) Aldosterone/renin ratio in the diagnosis of primary aldosteronism. Medicina (B Aires) 71(6):525–530
33.
Zurück zum Zitat Novitsky YW, Czerniach DR, Kercher KW, Perugini RA, Kelly JJ, Litwin DE (2003) Feasibility of laparoscopic adrenalectomy for large adrenal masses. Surg Laparosc Endosc Percutan Tech 13(2):106–110PubMedCrossRef Novitsky YW, Czerniach DR, Kercher KW, Perugini RA, Kelly JJ, Litwin DE (2003) Feasibility of laparoscopic adrenalectomy for large adrenal masses. Surg Laparosc Endosc Percutan Tech 13(2):106–110PubMedCrossRef
34.
Zurück zum Zitat Saeger W (1995) Pathology of adrenal neoplasms. Minerva Endocrinol 20(1):1–8PubMed Saeger W (1995) Pathology of adrenal neoplasms. Minerva Endocrinol 20(1):1–8PubMed
35.
Zurück zum Zitat Zeiger MA, Thompson GB, Duh QY et al (2009) The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 15(Suppl 1):1–20PubMedCrossRef Zeiger MA, Thompson GB, Duh QY et al (2009) The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 15(Suppl 1):1–20PubMedCrossRef
36.
Zurück zum Zitat Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E (2006) Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg 202(3):423–430PubMedCrossRef Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E (2006) Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg 202(3):423–430PubMedCrossRef
37.
Zurück zum Zitat Blumenfeld JD, Sealey JE, Schlussel Y et al (1994) Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 121(11):877–885PubMedCrossRef Blumenfeld JD, Sealey JE, Schlussel Y et al (1994) Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 121(11):877–885PubMedCrossRef
38.
Zurück zum Zitat Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP (2005) Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 12(1):149–159PubMedCrossRef Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP (2005) Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 12(1):149–159PubMedCrossRef
39.
Zurück zum Zitat Aubert S, Wacrenier A, Leroy X et al (2002) Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 26(12):1612–1619PubMedCrossRef Aubert S, Wacrenier A, Leroy X et al (2002) Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 26(12):1612–1619PubMedCrossRef
40.
Zurück zum Zitat Wu JC, Tang ZY, Zhang W et al (2006) Clinical characteristics and surgery outcomes of unilateral nodular adrenal hyperplasia in primary aldosteronism: study of 145 cases. Zhonghua Yi Xue Za Zhi 86(46):3302–3305PubMed Wu JC, Tang ZY, Zhang W et al (2006) Clinical characteristics and surgery outcomes of unilateral nodular adrenal hyperplasia in primary aldosteronism: study of 145 cases. Zhonghua Yi Xue Za Zhi 86(46):3302–3305PubMed
41.
Zurück zum Zitat Pang TC, Bambach C, Monaghan JC et al (2007) Outcomes of laparoscopic adrenalectomy for hyperaldosteronism. ANZ J Surg 77(9):768–773PubMedCrossRef Pang TC, Bambach C, Monaghan JC et al (2007) Outcomes of laparoscopic adrenalectomy for hyperaldosteronism. ANZ J Surg 77(9):768–773PubMedCrossRef
42.
Zurück zum Zitat Zarnegar R, Young WF Jr, Lee J et al (2008) The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 247(3):511–518PubMedCrossRef Zarnegar R, Young WF Jr, Lee J et al (2008) The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 247(3):511–518PubMedCrossRef
43.
Zurück zum Zitat Amar L, Plouin PF, Steichen O (2010) Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis 5:9PubMedCentralPubMedCrossRef Amar L, Plouin PF, Steichen O (2010) Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis 5:9PubMedCentralPubMedCrossRef
44.
Zurück zum Zitat Quillo AR, Grant CS, Thompson GB, Farley DR, Richards ML, Young WF (2011) Primary aldosteronism: results of adrenalectomy for nonsingle adenoma. J Am Coll Surg 213(1):106–112PubMedCrossRef Quillo AR, Grant CS, Thompson GB, Farley DR, Richards ML, Young WF (2011) Primary aldosteronism: results of adrenalectomy for nonsingle adenoma. J Am Coll Surg 213(1):106–112PubMedCrossRef
45.
Zurück zum Zitat Furuta N, Bando S, Yamamoto T et al (2013) The prevalence of hypertension after adrenalectomy in patients with primary aldosteronism. Hinyokika Kiyo 59(4):225–229PubMed Furuta N, Bando S, Yamamoto T et al (2013) The prevalence of hypertension after adrenalectomy in patients with primary aldosteronism. Hinyokika Kiyo 59(4):225–229PubMed
46.
Zurück zum Zitat Maluf DF, de Oliveira BH, Lalli E (2011) Therapy of adrenocortical cancer: present and future. Am J Cancer Res 1(2):222–232PubMedCentralPubMed Maluf DF, de Oliveira BH, Lalli E (2011) Therapy of adrenocortical cancer: present and future. Am J Cancer Res 1(2):222–232PubMedCentralPubMed
47.
Zurück zum Zitat Michalkiewicz E, Sandrini R, Figueiredo B et al (2004) Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 22(5):838–845PubMedCrossRef Michalkiewicz E, Sandrini R, Figueiredo B et al (2004) Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 22(5):838–845PubMedCrossRef
48.
Zurück zum Zitat Bilimoria KY, Shen WT, Elaraj D et al (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113(11):3130–3136PubMedCrossRef Bilimoria KY, Shen WT, Elaraj D et al (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113(11):3130–3136PubMedCrossRef
Metadaten
Titel
Predictors of malignancy in primary aldosteronism
verfasst von
Ayman Agha
Matthias Hornung
Igors Iesalnieks
Andreas Schreyer
Ernst Michael Jung
Assad Haneya
Hans J. Schlitt
Publikationsdatum
01.01.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 1/2014
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-013-1121-2

Weitere Artikel der Ausgabe 1/2014

Langenbeck's Archives of Surgery 1/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.